AI assistant
Sending…
REPLIGEN CORP — Director's Dealing 2019
Jun 12, 2019
30826_dirs_2019-06-11_ce4ef723-a133-40c1-a584-06027039e35b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2019-02-28
Reporting Person: KURIYEL RALF (Senior VP, R&D)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-02-28 | Stock Option (Right to Buy) | $59.52 | A | 4061 | Acquired | 2029-02-28 | Common Stock (4061) | Direct |
Footnotes
F1: One third of the stock options will vest and become exercisable annually on February 28, 2020, February 28, 2021 and February 28, 2022.
More from REPLIGEN CORP
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 5
Proxy Solicitation & Information Statement
2026
Apr 27
Annual Report
2026
Apr 2
Proxy Solicitation & Information Statement
2026
Apr 2
Proxy Solicitation & Information Statement
2026
Apr 2
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 23
Director's Dealing
2026
Mar 23